SCHEMBL1495313

SCHEMBL1495313

CC(C)COC(OCC(C)C)OCC(C)C

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.41
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.32
TSHR P16473 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL125895 0.77
SCHEMBL10574849 0.77 ALDH1A1 (0.38) ALDH1A1LMNATSHR
SCHEMBL1572578 0.77 LMNA (0.47) ALDH1A1LMNATSHR
SCHEMBL3900511 0.74 ALDH1A1 (0.36) ALDH1A1LMNA
SCHEMBL19467 0.72
SCHEMBL6179035 0.72 ALDH1A1 (0.35) ALDH1A1TSHR
SCHEMBL1263276 0.72
SCHEMBL8467687 0.72
SCHEMBL1263275 0.72
SCHEMBL16786171 0.72 ALDH1A1 (0.35) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119613414-A Non-azolanet Process for the preparation of tam 上海皓元医药股份有限公司 2025-03-14 CN claimed
US-12059467-B2 Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same ANHUI UNIVERSITY (CN) 2024-08-13 US claimed
US-20240108728-A1 IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME ANHUI UNIVERSITY (CN) 2024-04-04 US claimed
WO-2023221320-A1 IMPROVED LOW-TOXICITY AND HIGHLY EFFICIENT PHARMACEUTICAL EXCIPIENT OF ORTHOESTER MIXTURE, METHOD FOR PREPARING SAME, AND LOCAL SUSTAINED-RELEASE PREPARATION COMPRISING SAME 安徽大学 2023-11-23 WO claimed
CN-114848585-B Improved low-toxicity high-efficiency orthoester miscible medicinal adjuvant, preparation method and local sustained-release drug delivery preparation containing adjuvant 安徽大学 2023-03-28 CN claimed
CN-114848585-A Improved low-toxicity high-efficiency orthoester miscible medicine pharmaceutic adjuvant, preparation method and local sustained-release administration preparation containing adjuvant 安徽大学 2022-08-05 CN claimed
CN-111116423-A Process method for preparing tert-butyl isocyano 苏州百灵威超精细材料有限公司 2020-05-08 CN claimed
US-5932747-A Method for preparing 1,3-dioxane compounds HUELS AKTIENGESELLSCHAFT (DE) 1999-08-03 US claimed
US-5760275-A CATALYZING WITH CARBON MONOXIDE AND HYDROGEN IN PRESENCE OF GROUP 8 METAL COMPOUND AIR PRODUCTS AND CHEMICALS, INC. (US) 1998-06-02 US claimed
CN-121154837-B Crosslinked nano prodrug, nano self-assembled hydrogel precursor tablet prepared from crosslinked nano prodrug and application of nano self-assembled hydrogel precursor tablet ANHUI UNIVERSITY (CN) 2026-05-26 CN disclosed
CN-119613414-A Non-azolanet Process for the preparation of tam 上海皓元医药股份有限公司 2025-03-14 CN disclosed
US-12059467-B2 Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same ANHUI UNIVERSITY (CN) 2024-08-13 US disclosed
US-20240108728-A1 IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME ANHUI UNIVERSITY (CN) 2024-04-04 US disclosed
WO-2023221320-A1 IMPROVED LOW-TOXICITY AND HIGHLY EFFICIENT PHARMACEUTICAL EXCIPIENT OF ORTHOESTER MIXTURE, METHOD FOR PREPARING SAME, AND LOCAL SUSTAINED-RELEASE PREPARATION COMPRISING SAME 安徽大学 2023-11-23 WO disclosed
US-4001230-A ANTIBACTERIAL, ANTIPROTAZOAL ELI LILLY AND COMPANY (US) 1977-01-04 US disclosed
US-3988356-A Novel haptenes and antigens ROUSSEL-UCLAF (FR) 1976-10-26 US disclosed
US-3981717-A ANILINO COMPOUNDS AMERICAN CYANAMID COMPANY (US) 1976-09-21 US disclosed
US-3980794-A Method for promoting growth of poultry with 3-(5-nitro-2-imidazolyl)pyrazoles ELI LILLY AND COMPANY (US) 1976-09-14 US disclosed
US-3975413-A Novel haptenes and antigens PIERDET ANDRE 1976-08-17 US disclosed
US-3947467-A ANTIBACTERIAL, ANTIPROTOZOAL, ANTIFUNGAL ELI LILLY AND COMPANY (US) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108728-A1 IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME TLR7, PON1, MYD88 THRB 3938/4885ALDH1A1 1589/4885LMNA 4613/4885
US-12059467-B2 Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same TLR7, PON1, MYD88 THRB 3881/4885ALDH1A1 1529/4885LMNA 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.